Patents by Inventor Kendra N. Avery

Kendra N. Avery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6
    Publication number: 20240132584
    Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
    Type: Application
    Filed: July 5, 2023
    Publication date: April 25, 2024
    Inventors: Matthew S. Faber, Sung-Hyung Lee, Yoon Kyung Kim, Jing Qi, Kendra N. Avery, Seung Y. Chu, Alex Nisthal, Matthew J. Bernett, John R. Desjarlais, Chad Borchert
  • Heterodimeric antibodies that bind CD3 and CLDN6
    Patent number: 11739144
    Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: August 29, 2023
    Assignee: Xencor, Inc.
    Inventors: Matthew S. Faber, Sung-Hyung Lee, Yoon Kyung Kim, Jing Qi, Kendra N. Avery, Seung Y. Chu, Alex Nisthal, Matthew J. Bernett, John R. Desjarlais, Chad Borchert
  • DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS
    Publication number: 20230085485
    Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
    Type: Application
    Filed: April 25, 2022
    Publication date: March 16, 2023
    Inventors: John C. Williams, Cindy Zer, Kendra N. Avery, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
  • HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6
    Publication number: 20220289839
    Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
    Type: Application
    Filed: March 9, 2022
    Publication date: September 15, 2022
    Inventors: Matthew S. Faber, Sung-Hyung Lee, Yoon Kyung Kim, Jing Qi, Kendra N. Avery, Seung Y. Chu, Alex Nisthal, Matthew J. Bernett, John R. Desjarlais, Chad Borchert
  • Development of masked therapeutic antibodies to limit off-target effects
    Patent number: 11311622
    Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: April 26, 2022
    Assignees: City of Hope, Thomas Jefferson University
    Inventors: John C. Williams, Cindy Zer, Kendra N. Avery, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
  • DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS
    Publication number: 20200164077
    Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
    Type: Application
    Filed: July 2, 2019
    Publication date: May 28, 2020
    Applicant: Thomas Jefferson University
    Inventors: John C. Williams, Cindy Zer, Kendra N. Avery, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
  • Development of masked therapeutic antibodies to limit off-target effects
    Patent number: 10357571
    Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: July 23, 2019
    Assignees: Thomas Jefferson University, City of Hope
    Inventors: John C. Williams, Cindy Zer, Kendra N. Avery, Ulrich Rodeck, Joshua M. Donaldson, Csaba Kari
  • Meditopes and meditope-binding antibodies and uses thereof
    Patent number: 9669108
    Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: June 6, 2017
    Assignee: City of Hope
    Inventors: John C. Williams, David A. Horne, Yuelong Ma, Heng Wei Chang, Joshua M. Donaldson, Cindy Zer, Krzysztof Bzymek, Kendra N. Avery, Jun Xie
  • DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS
    Publication number: 20160144042
    Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
    Type: Application
    Filed: November 23, 2015
    Publication date: May 26, 2016
    Inventors: John C. WILLIAMS, Cindy ZER, Kendra N. AVERY
  • Development of masked therapeutic antibodies to limit off-target effects
    Patent number: 9193791
    Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
    Type: Grant
    Filed: March 19, 2012
    Date of Patent: November 24, 2015
    Assignee: City of Hope
    Inventors: John C. Williams, Cindy Zer, Kendra N. Avery
  • MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF
    Publication number: 20150030535
    Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
    Type: Application
    Filed: August 6, 2014
    Publication date: January 29, 2015
    Inventors: John C. WILLIAMS, David A. HORNE, Yuelong MA, Heng Wei CHANG, Joshua M. DONALDSON, Cindy ZER, Krzysztof BZYMEK, Kendra N. AVERY, Jun XIE
  • DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS
    Publication number: 20130060010
    Abstract: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
    Type: Application
    Filed: March 19, 2012
    Publication date: March 7, 2013
    Inventors: John C. Williams, Cindy Zer, Kendra N. Avery